Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Frostman who wrote (5144)	1/30/1998 3:12:00 PM
From: Tunica Albuginea	Read Replies (1) \| Respond to of 23519

Frostman, I can't comment factually because I don't know all the details. I would like to leave that to Gene. All I can say is: -If it is a cream they are delivering to the skin ( which is what I thought it was all along), it is dead in the water. Won't work, even if they have a olatinum plated patent on it. -Delivering a liquid in the urethra they are going uo against Vivus'patent. -If delivering Prostaglandin intraurethrally via liquid instead of a pellet as in MUSE was better, Vivus would have done it. -what they and Vivus have is the SAME drug: Alprostadil/Prostaglandin. How can one formulation ( MUSE) cause pain in some patients and the other, Harvard Scintific, cause none? Doesn't compute. -Considering the shennanigans going on with HVSF recently ( fired CEO or CFO because Waite wanted to have money outside of normal accounting practices ) makes me very suspicious. As far as goldstein, if he is paid well for his consultacy, why not take the job/money ( from HVSF ) even if the company flunks later? TA

To: Frostman who wrote (5144)	1/30/1998 3:19:00 PM
From: John J H Kim	Read Replies (2) \| Respond to of 23519

As a newcomer to the thread, just been doing some research into VVUS, and it's product muse. After finding out exactly what MUSE is, I must say, it gave me a little queasy feeling. I like many am not fond of needles. Although MUSE delivery system is not hyperdermic, I would like to know from someone who is more familiar with the product to assess how people might react to the nature of the delivery system. From an initial point of view it seems a little crude and maybe painful. If I were someone who was in need of erectile dysfunction treatment, I would tend to look for a pill or somekind of topical approach. I'm sure this issue has been discussed before, and if it has I apologize for bringing it up again. Is there a doctor in the house? Thanks

To: Frostman who wrote (5144)	1/30/1998 3:47:00 PM
From: RT	Read Replies (1) \| Respond to of 23519

Frostman, Thanks Frosty, you made my day. Sounds like another crisis in the making. Can't we get a break. If Harvards delivery systems was issued a patient similar to Vivus's, and it is painless, effective and does not need to be refrigerated we are in deep dodo. However, if all was well with Harvard Scientific why is their stock trading at .96 cents. It seems to me, it should have gone up several dollars, instead of .20 cents. If this company is for real, then Vivus should consider buying them out before we have some serious competition. I suspect, as I speak Vivus's lawyers are filing a patient infringment lawsuit against Harvard. Whats your take on this situation? RT PS. We better win this lawsuit or it could be all over for Vivus. IMO